Impact of ETI Treatment on CF Patients with Rare Variants (Non-F508del)
发布者：Unknown
·发布于: 2025-12-13
Discussion regarding how elexacaftor/tezacaftor/ivacaftor (ETI) treatment affects lung function and pulmonary exacerbation rates specifically in cystic fibrosis patients with rare CFTR variants who lack the F508del mutation.